Amgen Inc. News
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
see moreAmgen Inc. Market News
8h
Amgen Rally: Q4 Beat, MariTide & Oncology Buy Now!
- Amgen's recent quarterly beat, stronger-than-expected product sales and a targeted oncology acquisition have pushed AMGN toward 52-week highs. Momentum centers on Repatha and Prolia performance, six active MariTide obesity trials, and the Dark Blue Therapeutics deal that expands Amgen's degrader oncology work.
7d
Amgen Rally, Lawsuit Risks, Earnings & Dividend Up
Amgen shares hit fresh 52-week highs this week amid technical buying and a dividend raise, but a new lawsuit and muted trading volume add near-term risk ahead of Q4 earnings on Feb 3.
14d
Amgen MariTide Data, Dark Blue Deal Boost AMGN Now
Recent concrete developments — strong Phase 2 MariTide obesity data and Amgen’s acquisition of Dark Blue Therapeutics — have created tangible near-term catalysts for AMGN. Combined with a dividend increase and analyst target upgrades, these events reinforce Amgen’s diversification into obesity and targeted oncology and provide potential upside triggers for the stock.
21d
Amgen MariTide Phase2 Data Sparks AMGN Rally Today
Amgen’s recent Phase 2 extension results for MariTide—released at the J.P. Morgan Healthcare Conference—show durable weight loss with lower dosing and improved tolerability, creating a near-term positive catalyst for AMGN. Technical indicators and volume support growing investor interest as Amgen holds up better than many pharma peers.
28d
Amgen Buys Dark Blue: Boost to AML Pipeline, $840M
Amgen’s $840M acquisition of Dark Blue Therapeutics strengthens its oncology pipeline—adding a targeted protein‑degradation AML candidate—and arrived amid a sector rotation that pushed AMGN shares lower. The deal is a mid‑term pipeline catalyst while short‑term price moves reflect broader investor sentiment.
31 Dec at 07:26
Amgen Faces Biosimilar Threat, Gains Credit Boost.
Recent FDA approvals for denosumab biosimilars (Prolia/XGEVA rivals) and a Fitch upgrade to BBB+ created a mixed catalyst for Amgen (AMGN). Strong Q3 2025 results and continued debt reduction support financial resilience, while biosimilar entry and U.S. drug‑pricing moves pose near‑to‑longer‑term revenue pressures.
24 Dec at 07:25
Amgen: Biosimilar Threat vs Fitch Upgrade Strength
This week Amgen (AMGN) faced a notable dual narrative: the FDA cleared denosumab biosimilars that threaten Prolia and XGEVA revenues, while Fitch upgraded Amgen’s credit rating to BBB+, reflecting improved balance-sheet resilience. Additional developments — a federal drug‑pricing agreement, FDA approval for UPLIZNA, ongoing MariTide program watch, and solid Q3 results with raised guidance — create offsetting forces. Investors should weigh near‑term revenue pressure from biosimilars against financial stability and upcoming clinical and regulatory catalysts.